SE0103423D0 - polymorphism - Google Patents

polymorphism

Info

Publication number
SE0103423D0
SE0103423D0 SE0103423A SE0103423A SE0103423D0 SE 0103423 D0 SE0103423 D0 SE 0103423D0 SE 0103423 A SE0103423 A SE 0103423A SE 0103423 A SE0103423 A SE 0103423A SE 0103423 D0 SE0103423 D0 SE 0103423D0
Authority
SE
Sweden
Prior art keywords
multiple sclerosis
lag3
polymorphism
predisposition
seq
Prior art date
Application number
SE0103423A
Other languages
Swedish (sv)
Inventor
Dennis Hellgren
Zhiping Zhang
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0103423A priority Critical patent/SE0103423D0/en
Publication of SE0103423D0 publication Critical patent/SE0103423D0/en
Priority to PCT/SE2002/001859 priority patent/WO2003031655A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

This invention relates to a method for the diagnosis of multiple sclerosis by genetic analysis. The method includes determining the nucleic acid sequence of LAG3 in a subject at position 1364 in the coding region of the LAG3 gene as defined by the position in SEQ ID NO: 1, wherein the presence of a T at position 1364 is diagnostic of multiple sclerosis or a predisposition thereto.
SE0103423A 2001-10-12 2001-10-12 polymorphism SE0103423D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
SE0103423A SE0103423D0 (en) 2001-10-12 2001-10-12 polymorphism
PCT/SE2002/001859 WO2003031655A1 (en) 2001-10-12 2002-10-11 Method for diagnosis of multiple sclerosis by genetic analysis of the lag3 gene

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0103423A SE0103423D0 (en) 2001-10-12 2001-10-12 polymorphism

Publications (1)

Publication Number Publication Date
SE0103423D0 true SE0103423D0 (en) 2001-10-12

Family

ID=20285649

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0103423A SE0103423D0 (en) 2001-10-12 2001-10-12 polymorphism

Country Status (2)

Country Link
SE (1) SE0103423D0 (en)
WO (1) WO2003031655A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1826277A1 (en) 2006-02-27 2007-08-29 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Methods for predicting the response of multiple sclerosis patients to interferon therapy and diagnosing multiple sclerosis
EP2380992A1 (en) 2010-04-21 2011-10-26 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Methods for predicting an antibody response to interfer on therapy in multiple sclerosis patients
JO3663B1 (en) 2014-08-19 2020-08-27 Merck Sharp & Dohme Anti-lag3 antibodies and antigen-binding fragments
WO2017106129A1 (en) 2015-12-16 2017-06-22 Merck Sharp & Dohme Corp. Anti-lag3 antibodies and antigen-binding fragments

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2656800B1 (en) * 1990-01-08 1992-05-15 Roussy Inst Gustave NEW PROTEINS PRODUCED BY HUMAN LYMPHOCYTES, DNA SEQUENCE ENCODING THESE PROTEINS AND PHARMACEUTICAL AND BIOLOGICAL APPLICATIONS.
EP0900841A1 (en) * 1997-06-18 1999-03-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) LAG-3 splice variants

Also Published As

Publication number Publication date
WO2003031655A1 (en) 2003-04-17

Similar Documents

Publication Publication Date Title
EP0757723A4 (en) GENETIC CHANGES CORRELING WITH LUNG CARCINOMAS
SG134283A1 (en) Biomarkers for liver fibrotic injury
CY1108716T1 (en) METHOD OF DIAGNOSIS OF ALZHEIMER'S DISEASE BASED ON A FORM OF TRANSMISSION OF GENE.
WO2003027309A3 (en) Diagnostic probe detection system
EP2474630A3 (en) Genetic polymorphisms associated with myocardial infarction, methods of detection and uses thereof
EA199700355A1 (en) METHOD OF DIAGNOSTIC SCHIZOPHRENIA
ATE336591T1 (en) DETECTION METHODS FOR SHORT SEQUENCE VARIANTS
DE69531309D1 (en) DESIGN OF DISCONTINUOUS PROBES USING HYBRITOPEMAPPING
IL145607A0 (en) Diagnostic sequencing by a combination of specific cleavage and mass spectrometry
DE60043944D1 (en) ZYTOKIN ZCYT018
ATE485391T1 (en) COMPOSITIONS, METHODS AND TEST SYSTEMS FOR DETERMINING THE PRESENCE OF CRYPTOSPORIDIUM ORGANISMS IN A TEST SAMPLE
ATE542917T1 (en) COMPOSITIONS, METHODS AND KITS FOR DETERMINING THE PRESENCE OF TRICHOMONAS VAGINALIS IN A TEST SAMPLE
EP1531180A4 (en) Method of diagnosing risk of myocardial infarction
SE0103423D0 (en) polymorphism
DE602006012995D1 (en) BREAST CANCER DIAGNOSTIC PROCEDURE
WO2003014879A3 (en) System and method for identifying a genetic risk factor for a disease or pathology
FR2876705B1 (en) METHOD FOR THE DIAGNOSIS OF ASPIRIN INTOLERANCE
WO2002046468A3 (en) Method for maldi-tof-ms analysis and/or sequencing of oligonucleotides
FI990380A7 (en) Diagnostic and screening method
DE60334408D1 (en) NSÄUREN
GB0120437D0 (en) Diabetic model
ATE459646T1 (en) DIAGNOSTIC METHOD FOR CANCER CHARACTERIZED BY DETECTION OF G-CSF EXON 3 DELETION
WO2007050735A3 (en) Markers for production traits
WO2006029256A3 (en) Compositions, methods, and systems for determining bovine parentage and identity
EP1038025A4 (en) GENETIC MODIFICATIONS ASSOCIATED WITH CANCER